P
Pradip Rustagi
Researcher at Stanford University
Publications - 9
Citations - 3653
Pradip Rustagi is an academic researcher from Stanford University. The author has contributed to research in topics: Factor IX & ELISPOT. The author has an hindex of 7, co-authored 9 publications receiving 3303 citations.
Papers
More filters
Journal ArticleDOI
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
Catherine S. Manno,Glenn F. Pierce,Valder R. Arruda,Bertil Glader,Margaret V. Ragni,Rasko Jj,Margareth C. Ozelo,Keith Hoots,Blatt P,Barbara A. Konkle,Michael D. Dake,Robin D. Kaye,Mahmood K. Razavi,A Zajko,James L. Zehnder,Pradip Rustagi,Hiroyuki Nakai,A Chew,Debra G.B. Leonard,Debra G.B. Leonard,J F Wright,Ruth Lessard,Jurg M. Sommer,Michael Tigges,Denise E. Sabatino,A Luk,Haiyan Jiang,Federico Mingozzi,Linda B. Couto,Hildegund C.J. Ertl,Katherine A. High,Katherine A. High,Mark A. Kay +32 more
TL;DR: In this article, a single portal vein infusion of a recombinant adeno-associated viral vector (rAAV) expressing canine Factor IX (F.IX) resulted in long-term expression of therapeutic levels of F.IX in dogs with severe hemophilia B.
Journal ArticleDOI
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani,Edward G. D. Tuddenham,Savita Rangarajan,Cecilia Rosales,Jenny McIntosh,David C. Linch,Pratima Chowdary,Anne Riddell,Arnulfo Jaquilmac Pie,Chris Harrington,James O'Beirne,Keith Smith,John Pasi,Bertil Glader,Pradip Rustagi,Catherine Y.C. Ng,Mark A. Kay,Junfang Zhou,Yunyu Spence,Christopher L. Morton,James A. Allay,John Coleman,Susan Sleep,John M. Cunningham,Deokumar Srivastava,Etiena Basner-Tschakarjan,Federico Mingozzi,Katherine A. High,John T. Gray,Ulrike M. Reiss,Arthur W. Nienhuis,Andrew M. Davidoff +31 more
TL;DR: Peripheral-vein infusion of scAAV2/8-LP1-hFIXco resulted in FIX transgene expression at levels sufficient to improve the bleeding phenotype, with few side effects.
Journal ArticleDOI
1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B
Katherine A. High,Catherine S. Manno,Denise E. Sabatino,Sylvia Hutchison,Michael D. Dake,Mahmood K. Razavi,Robin D. Kaye,Valder Aruda,Roland W. Herzog,Pradip Rustagi,John E.J. Rasko,Keith Hoots,Phillip Blatt,Jurg M. Sommer,Margaret V. Ragni,Margareth C. Ozelo,Barbara A. Konkle,Ruth Lessard,Alvin Luk,Bertil Glader,Glenn F. Pierce,Linda B. Couto,Mark A. Kay +22 more
TL;DR: It is concluded that AAV-F.IX can transduce human hepatocytes in vivo, resulting in therapeutic circulating factor levels and the vector dose required to achieve a therapeutic factor level was accurately predicted by animal models.
Early clinical trial results following administration of a low dose of a novel self complementary adenohyphen;associated viral vector encoding human factor ix in two subjects with severe Haemophilia B
Amit C. Nathwani,Egd Tuddenham,Cecilia Rosales,Jenny McIntosh,Anne Riddell,Pradip Rustagi,B Galder,Mark A. Kay,James A. Allay,John Coleman,Susan Sleep,Katherine A. High,Federico Mingozzi,John T. Gray,Ulrike M. Reiss,Arthur W. Nienhuis,Andrew M. Davidoff +16 more
Journal ArticleDOI
Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B
Amit C. Nathwani,Edward G. D. Tuddenham,Cecilia Rosales,Jenny McIntosh,Anne Riddell,Pradip Rustagi,Bertil Glader,Mark A. Kay,James A. Allay,John Coleman,Susan Sleep,Katherine A. High,Federico Mingozzi,John T. Gray,Ulrike M. Reiss,Arthur W. Nienhuis,Andrew M. Davidoff +16 more
TL;DR: There were no adverse reactions during vector infusion and no subsequent evidence of hepatotoxicity, and there were no significant changes in the complete blood count and serum chemistry panel.